DDrare: Database of Drug Development for Rare Diseases

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (2)-epigallocatechin-3-gallate (EGCG); 20 mg BID of PF-02545920; 20mg daily citalopram; 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium; ACR16; ACR16 10 mg; ACR16 22.5 mg; ACR16 45 mg; ACR16 hydrochloride, ASP2314 hydrochloride, FR310826; AFQ056; ANX005; Alprazolam; Amantadine; Anti-Parkinson medication; Atomoxetine; Autologous Stem Cell; BEVANTOLOL HYDROCHLORIDE; BN82451B; BN8251B; Bevantolol; Biotin; Blood sample; Bupropion; CBD; CKD-504; CYSTAGON; Calvan® 100 mg; Cannabidiol; Cellavita HD Higher dose; Cellavita HD Lower Dose; Cellavita HD higher dose; Cellavita HD lower dose; Cellavita-HD; Citalopram; CoQ10; Coenzyme Q10; Creatine; Creatine Monohydrate; Creatine monohydrate; Cystagon; Cysteamine; Cysteamine Bitartrate; DM; Delta-9-tetrahydrocannabinol; Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD); Deutetrabenazine; Deutetrabenazine Oral Tablet [Austedo]; Device: BioStamp nPoint device; Device: Deep Brain Stimulation; Dextromethorphan; Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg); Digoxin; Dimebon; Dimebon (latrepirdine); Dimebon + Dextromethorphan; Dimebon + Ketoconazole; Dimebon + Omeprazole; Dimebon Dihydrochloride; Dimebon IR; Dimebon IR Tablet; Dimebon MR1; Dimebon MR2; Dimebon MR3; Dimebon MR4; Dimebon Transdermal; Dimebon alone; Dimebon dihydrochloride; Divalproex; EGCG; EPA; Epigallocatechin; Ethyl Icosapent; Ethyl-EPA; Ethyl-EPA (Miraxion™); Ethyl-Icosapent; Fenofibrate; GSK356278; Graft intracerebral of foetal neurons; HYPERIUM; Haloperidol; High doses of Thiamine y Biotin; Hyperium; ISIS 443139 10 mg; ISIS 443139 120 mg; ISIS 443139 30 mg; ISIS 443139 60 mg; ISIS 443139 90 mg; Icosapent; Ketoconazole; LAQUINIMOD; LAX-101; Laquinimod; Laquinimod capsules 0.5 mg; Latrepirdine; Lithium; Melatonin; Memantine; Minocycline; Moderate doses of Thiamine y Biotin; N.a.; Neflamapimod; Nilotinib; Nilotinib 150 MG; OMS643762; OSU6162 similar to (-)-OSU 6162; Olanzapine; Omeprazole; Other: 31-Phosphorus RMN Spectroscopy; PBF-999; PBF-999 / 160 mg; PBF-999 / 320 mg; PBT2; PF-02545920; PL101; PRIDOPIDINE HYDROCHLORIDE; Phenylbutyrate; Phosphorus; Pridiopidine; Pridopidina; Pridopidine; Pridopidine (90 mg); Quinidine; RG6042, formerly ISIS 443139, IONIS-HTTRx; RO7234292; RO7234292 (RG6042); RP 103; RP103; Ramelteon; Resveratrol; Rilmenidine; Riluzole; Risperidone; Ro 723-4292/F02; Rolipram; SAGE-718; SBT-020; SD-809; SEN0014196; SEN0014196 (High Dose); SEN0014196 (Low Dose); SOM3355 100mg BID; SOM3355 200mg BID; SRX246; SS-20; Selisistat; Sodium phenylbutyrate; THC; TV-5600; TV-7820; Tetrabenazine; Tetrabenazine withdrawal; Tetrahydrocannabinol; Thiamine; Tiapridal; Tominersen; Triheptanoin; Triheptanoin 1g/kg/day; Triheptanoin oil; UX007; Ubiquinol; Ursodiol; VX-745; VX15/2503; Valbenazine; WVE-120101; WVE-120102; Warfarin; Xenazine; Zoloft; [123I]MNI-420; [18F]FPEB

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-002088-98-PT (EUCTR)	07/06/2006	16/03/2006	Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease	Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease	HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331	Product Name: Ethyl-EPA Product Code: LAX-101 INN or Proposed INN: Ethyl Icosapent Other descriptive name: Ethyl-EPA	Amarin Neuroscience Ltd	NULL	Not Recruiting			Female: yes Male: yes			Portugal;Germany;United Kingdom;Spain;Italy
2	EUCTR2005-002088-98-ES (EUCTR)	29/12/2005	04/10/2005	Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington.	Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington.	HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: llt;Classification code 10010331	Product Name: Ethyl-EPA Product Code: LAX-101	Amarin Neuroscience Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Portugal;Germany;United Kingdom;Spain;Italy
3	EUCTR2005-002088-98-AT (EUCTR)	01/12/2005	27/10/2005	Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease	Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease	HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331	Product Name: Ethyl-EPA Product Code: LAX-101 INN or Proposed INN: Ethyl-Icosapent	Amarin Neuroscience Ltd	NULL	Not Recruiting			Female: yes Male: yes	240		Portugal;Spain;Austria;Germany;Italy;United Kingdom
4	EUCTR2005-002088-98-GB (EUCTR)	07/11/2005	18/08/2005	Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease	Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease	HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331	Product Name: Ethyl-EPA Product Code: LAX-101	Amarin Neuroscience Ltd	NULL	Not Recruiting			Female: yes Male: yes			Portugal;Germany;United Kingdom;Spain;Italy
5	NCT00146211 (ClinicalTrials.gov)	September 2005	2/9/2005	TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease	A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease	Huntington Disease	Drug: Ethyl-EPA (Miraxion™)	Amarin Neuroscience Ltd	Huntington Study Group	Completed	35 Years	N/A	Both	300	Phase 3	United States;Canada
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2005-002088-98-DE (EUCTR)		28/11/2006	Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease	Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease	HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331	Product Name: Ethyl-EPA Product Code: LAX-101 INN or Proposed INN: Ethyl-Icosapent	Amarin Neuroscience Ltd	NULL	Not Recruiting			Female: yes Male: yes	240		Portugal;United Kingdom;Germany;Spain;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2005-002088-98-PT
(EUCTR)

07/06/2006

16/03/2006

Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease

HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331

Product Name: Ethyl-EPA
Product Code: LAX-101
INN or Proposed INN: Ethyl Icosapent
Other descriptive name: Ethyl-EPA

Amarin Neuroscience Ltd

NULL

Not Recruiting

Female: yes
Male: yes

Portugal;Germany;United Kingdom;Spain;Italy

EUCTR2005-002088-98-ES
(EUCTR)

29/12/2005

04/10/2005

Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington.

HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: llt;Classification code 10010331

Product Name: Ethyl-EPA
Product Code: LAX-101

Amarin Neuroscience Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Portugal;Germany;United Kingdom;Spain;Italy

EUCTR2005-002088-98-AT
(EUCTR)

01/12/2005

27/10/2005

Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease

HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331

Product Name: Ethyl-EPA
Product Code: LAX-101
INN or Proposed INN: Ethyl-Icosapent

Amarin Neuroscience Ltd

NULL

Not Recruiting

Female: yes
Male: yes

240

Portugal;Spain;Austria;Germany;Italy;United Kingdom

EUCTR2005-002088-98-GB
(EUCTR)

07/11/2005

18/08/2005

Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease

HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331

Product Name: Ethyl-EPA
Product Code: LAX-101

Amarin Neuroscience Ltd

NULL

Not Recruiting

Female: yes
Male: yes

Portugal;Germany;United Kingdom;Spain;Italy

NCT00146211
(ClinicalTrials.gov)

September 2005

2/9/2005

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease

Huntington Disease

Drug: Ethyl-EPA (Miraxion™)

Amarin Neuroscience Ltd

Huntington Study Group

Completed

35 Years

N/A

Both

300

Phase 3

United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2005-002088-98-DE
(EUCTR)

28/11/2006

Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease

HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331

Product Name: Ethyl-EPA
Product Code: LAX-101
INN or Proposed INN: Ethyl-Icosapent

Amarin Neuroscience Ltd

NULL

Not Recruiting

Female: yes
Male: yes

240

Portugal;United Kingdom;Germany;Spain;Italy